These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38970077)

  • 1. Predicting progression from subjective cognitive decline to mild cognitive impairment or dementia based on brain atrophy patterns.
    Lerch O; Ferreira D; Stomrud E; van Westen D; Tideman P; Palmqvist S; Mattsson-Carlgren N; Hort J; Hansson O; Westman E
    Alzheimers Res Ther; 2024 Jul; 16(1):153. PubMed ID: 38970077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparing a pre-defined versus deep learning approach for extracting brain atrophy patterns to predict cognitive decline due to Alzheimer's disease in patients with mild cognitive symptoms.
    Arvidsson I; Strandberg O; Palmqvist S; Stomrud E; Cullen N; Janelidze S; Tideman P; Heyden A; Åström K; Hansson O; Mattsson-Carlgren N
    Alzheimers Res Ther; 2024 Mar; 16(1):61. PubMed ID: 38504336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort.
    Caminiti SP; Ballarini T; Sala A; Cerami C; Presotto L; Santangelo R; Fallanca F; Vanoli EG; Gianolli L; Iannaccone S; Magnani G; Perani D;
    Neuroimage Clin; 2018; 18():167-177. PubMed ID: 29387532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural magnetic resonance imaging for the early diagnosis of dementia due to Alzheimer's disease in people with mild cognitive impairment.
    Lombardi G; Crescioli G; Cavedo E; Lucenteforte E; Casazza G; Bellatorre AG; Lista C; Costantino G; Frisoni G; Virgili G; Filippini G
    Cochrane Database Syst Rev; 2020 Mar; 3(3):CD009628. PubMed ID: 32119112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heterogeneity of Amyloid Binding in Cognitively Impaired Patients Consecutively Recruited from a Memory Clinic: Evaluating the Utility of Quantitative 18F-Flutemetamol PET-CT in Discrimination of Mild Cognitive Impairment from Alzheimer's Disease and Other Dementias.
    Bao YW; Chau ACM; Chiu PK; Shea YF; Kwan JSK; Chan FHW; Mak HK
    J Alzheimers Dis; 2021; 79(2):819-832. PubMed ID: 33361593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Automated Brain MRI Volumetry Differentiates Early Stages of Alzheimer's Disease From Normal Aging.
    Zhao W; Luo Y; Zhao L; Mok V; Su L; Yin C; Sun Y; Lu J; Shi L; Han Y
    J Geriatr Psychiatry Neurol; 2019 Nov; 32(6):354-364. PubMed ID: 31480984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biomarker-Based Prediction of Progression to Dementia: F-18 FDG-PET in Amnestic MCI.
    Tripathi M; Tripathi M; Parida GK; Kumar R; Dwivedi S; Nehra A; Bal C
    Neurol India; 2019; 67(5):1310-1317. PubMed ID: 31744965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A generalizable data-driven model of atrophy heterogeneity and progression in memory clinic settings.
    Baumeister H; Vogel JW; Insel PS; Kleineidam L; Wolfsgruber S; Stark M; Gellersen HM; Yakupov R; Schmid MC; Lüsebrink F; Brosseron F; Ziegler G; Freiesleben SD; Preis L; Schneider LS; Spruth EJ; Altenstein S; Lohse A; Fliessbach K; Vogt IR; Bartels C; Schott BH; Rostamzadeh A; Glanz W; Incesoy EI; Butryn M; Janowitz D; Rauchmann BS; Kilimann I; Goerss D; Munk MH; Hetzer S; Dechent P; Ewers M; Scheffler K; Wuestefeld A; Strandberg O; van Westen D; Mattsson-Carlgren N; Janelidze S; Stomrud E; Palmqvist S; Spottke A; Laske C; Teipel S; Perneczky R; Buerger K; Schneider A; Priller J; Peters O; Ramirez A; Wiltfang J; Heneka MT; Wagner M; Düzel E; Jessen F; Hansson O; Berron D
    Brain; 2024 Jul; 147(7):2400-2413. PubMed ID: 38654513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Altered Neuroanatomical Asymmetries of Subcortical Structures in Subjective Cognitive Decline, Amnestic Mild Cognitive Impairment, and Alzheimer's Disease.
    Fu Z; Zhao M; Wang X; He Y; Tian Y; Yang Y; Han Y; Li S
    J Alzheimers Dis; 2021; 79(3):1121-1132. PubMed ID: 33386805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longitudinal progression of Alzheimer's-like patterns of atrophy in normal older adults: the SPARE-AD index.
    Davatzikos C; Xu F; An Y; Fan Y; Resnick SM
    Brain; 2009 Aug; 132(Pt 8):2026-35. PubMed ID: 19416949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change.
    Vemuri P; Wiste HJ; Weigand SD; Shaw LM; Trojanowski JQ; Weiner MW; Knopman DS; Petersen RC; Jack CR;
    Neurology; 2009 Jul; 73(4):294-301. PubMed ID: 19636049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer's disease in individuals with subjective cognitive decline.
    Stockmann J; Verberk IMW; Timmesfeld N; Denz R; Budde B; Lange-Leifhelm J; Scheltens P; van der Flier WM; Nabers A; Teunissen CE; Gerwert K
    Alzheimers Res Ther; 2020 Dec; 12(1):169. PubMed ID: 33357241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integration and relative value of biomarkers for prediction of MCI to AD progression: spatial patterns of brain atrophy, cognitive scores, APOE genotype and CSF biomarkers.
    Da X; Toledo JB; Zee J; Wolk DA; Xie SX; Ou Y; Shacklett A; Parmpi P; Shaw L; Trojanowski JQ; Davatzikos C;
    Neuroimage Clin; 2014; 4():164-73. PubMed ID: 24371799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural neuroimaging changes associated with subjective cognitive decline from a clinical sample.
    Riverol M; Ríos-Rivera MM; Imaz-Aguayo L; Solis-Barquero SM; Arrondo C; Montoya-Murillo G; Villino-Rodríguez R; García-Eulate R; Domínguez P; Fernández-Seara MA
    Neuroimage Clin; 2024; 42():103615. PubMed ID: 38749146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subjective Spatial Navigation Complaints - A Frequent Symptom Reported by Patients with Subjective Cognitive Decline, Mild Cognitive Impairment and Alzheimer's Disease.
    Cerman J; Andel R; Laczo J; Vyhnalek M; Nedelska Z; Mokrisova I; Sheardova K; Hort J
    Curr Alzheimer Res; 2018; 15(3):219-228. PubMed ID: 29165083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baseline structural MRI and plasma biomarkers predict longitudinal structural atrophy and cognitive decline in early Alzheimer's disease.
    Xie L; Das SR; Wisse LEM; Ittyerah R; de Flores R; Shaw LM; Yushkevich PA; Wolk DA;
    Alzheimers Res Ther; 2023 Apr; 15(1):79. PubMed ID: 37041649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Basal forebrain atrophy correlates with amyloid β burden in Alzheimer's disease.
    Kerbler GM; Fripp J; Rowe CC; Villemagne VL; Salvado O; Rose S; Coulson EJ;
    Neuroimage Clin; 2015; 7():105-13. PubMed ID: 25610772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cerebrospinal fluid synaptosomal-associated protein 25 is a key player in synaptic degeneration in mild cognitive impairment and Alzheimer's disease.
    Zhang H; Therriault J; Kang MS; Ng KP; Pascoal TA; Rosa-Neto P; Gauthier S;
    Alzheimers Res Ther; 2018 Aug; 10(1):80. PubMed ID: 30115118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amyloid-Independent Amnestic Mild Cognitive Impairment and Serum Apolipoprotein A1 Levels.
    Choi HJ; Seo EH; Yi D; Sohn BK; Choe YM; Byun MS; Lee JM; Woo JI; Lee DY
    Am J Geriatr Psychiatry; 2016 Feb; 24(2):144-53. PubMed ID: 26238231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo detection of microstructural correlates of brain pathology in preclinical and early Alzheimer Disease with magnetic resonance imaging.
    Zhao Y; Raichle ME; Wen J; Benzinger TL; Fagan AM; Hassenstab J; Vlassenko AG; Luo J; Cairns NJ; Christensen JJ; Morris JC; Yablonskiy DA
    Neuroimage; 2017 Mar; 148():296-304. PubMed ID: 27989773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.